AbbVie acquires Aliada Therapeutics in $1.4 billion deal
The acquisition of Aliada Therapeutics will grant AbbVie access to a neuroscience-focused technology platform and an Alzheimer's drug candidate originally developed by Johnson & Johnson.
Archives for October 30, 2024